107 - John F. Enders Lecture

Speaker(s)

• 

  Anna Wald, MD, MPH

  Professor of Medicine
  University of Washington
  Seattle, Washington

  Disclosure: Aicuris : Consultant (Status: Ongoing); Gilead : Consultant (Status: Ongoing); GlaxoSmithKline : Scientific Research Study Investigator (Status: Ongoing); Merck : DSMB participation; provision of vaccine for a study (Status: Ongoing), Other Financial or Material Support (Status: Ongoing); Sanofi : Scientific Research Study Investigator (Status: Ongoing); X-Vax : Consultant (Status: Ongoing)

CME Credits: Maximum of 0.5 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 0.5 hours of MOC Credit

No CPE Credits

Learning Objectives:

• explain the role of endpoints in vaccine development
• describe the current issues with vaccine development
• discuss potential alternative approaches

Presentations:

• 10:30am – 11:00am EDT

  Developing Vaccines for Old and New Pathogens
  Anna Wald, MD, MPH – University of Washington